Literature DB >> 23231993

Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterations.

Eduardo M Castaño1, Chera L Maarouf, Terence Wu, Maria Celeste Leal, Charisse M Whiteside, Lih-Fen Lue, Tyler A Kokjohn, Marwan N Sabbagh, Thomas G Beach, Alex E Roher.   

Abstract

The white matter (WM) represents approximately half the cerebrum volume and is profoundly affected in Alzheimer's disease (AD). However, both the WM responses to AD as well as potential influences of this compartment to dementia pathogenesis remain comparatively neglected. Neuroimaging studies have revealed WM alterations are commonly associated with AD and renewed interest in examining the pathologic basis and importance of these changes. In AD subjects, immunohistochemistry and electron microscopy revealed changes in astrocyte morphology and myelin loss as well as up to 30% axonal loss in areas of WM rarefaction when measured against non-demented control (NDC) tissue. Comparative proteomic analyses were performed on pooled samples of periventricular WM (PVWM) obtained from AD (n=4) and NDC (n=5) subjects with both groups having a mean age of death of 86 years. All subjects had an apolipoprotein E ε3/3 genotype with the exception of one NDC subject who was ε2/3. Urea-detergent homogenates were analyzed using two different separation techniques: 2-dimensional isoelectric focusing/reverse-phase chromatography and 2-dimensional difference gel electrophoresis (2D-DIGE). Proteins with different expression levels between the 2 diagnostic groups were identified using MALDI-Tof/Tof mass spectrometry. In addition, Western blots were used to quantify proteins of interest in individual AD and NDC cases. Our proteomic studies revealed that when WM protein pools were loaded at equal amounts of total protein for comparative analyses, there were quantitative differences between the 2 groups. Molecules related to cytoskeleton maintenance, calcium metabolism and cellular survival such as glial fibrillary acidic protein, vimentin, tropomyosin, collapsin response mediator protein-2, calmodulin, S100-P, annexin A1, α-internexin, α- and β-synuclein, α-B-crystalline, fascin-1, ubiquitin carboxyl-terminal esterase and thymosine were altered between AD and NDC pools. Our experiments suggest that WM activities become globally impaired during the course of AD with significant morphological, biochemical and functional consequential implications for gray matter function and cognitive deficits. These observations may endorse the hypothesis that WM dysfunction is not only a consequence of AD pathology, but that it may precipitate and/or potentiate AD dementia.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23231993      PMCID: PMC3568229          DOI: 10.1016/j.neuint.2012.12.001

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  83 in total

1.  Measurement of global brain atrophy in Alzheimer's disease with unsupervised segmentation of spin-echo MRI studies.

Authors:  A Brunetti; A Postiglione; E Tedeschi; A Ciarmiello; M Quarantelli; E M Covelli; G Milan; M Larobina; A Soricelli; A Sodano; B Alfano
Journal:  J Magn Reson Imaging       Date:  2000-03       Impact factor: 4.813

2.  Oligomers of mutant glial fibrillary acidic protein (GFAP) Inhibit the proteasome system in alexander disease astrocytes, and the small heat shock protein alphaB-crystallin reverses the inhibition.

Authors:  Guomei Tang; Ming D Perng; Sherwin Wilk; Roy Quinlan; James E Goldman
Journal:  J Biol Chem       Date:  2010-01-28       Impact factor: 5.157

Review 3.  Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

Authors: 
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

4.  White matter pathology isolates the hippocampal formation in Alzheimer's disease.

Authors:  D H Salat; D S Tuch; A J W van der Kouwe; D N Greve; V Pappu; S Y Lee; N D Hevelone; A K Zaleta; J H Growdon; S Corkin; B Fischl; H D Rosas
Journal:  Neurobiol Aging       Date:  2010-02       Impact factor: 4.673

5.  Fibrillar amyloid-beta peptides activate microglia via TLR2: implications for Alzheimer's disease.

Authors:  Malabendu Jana; Carlos A Palencia; Kalipada Pahan
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

6.  Glial fibrillary acidic protein and Alzheimer-type senile dementia.

Authors:  P E Duffy; M Rapport; L Graf
Journal:  Neurology       Date:  1980-07       Impact factor: 9.910

7.  Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1996-08       Impact factor: 17.088

8.  Proteomic analysis of rat plasma by two-dimensional liquid chromatography and matrix-assisted laser desorption ionization time-of-flight mass spectrometry.

Authors:  Thomas Linke; A Catharine Ross; Earl H Harrison
Journal:  J Chromatogr A       Date:  2006-02-02       Impact factor: 4.759

9.  Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease.

Authors:  Oda-Christina Suter; Thanomphone Sunthorn; Rudolf Kraftsik; Joel Straubel; Pushpa Darekar; Kamel Khalili; Judith Miklossy
Journal:  Stroke       Date:  2002-08       Impact factor: 7.914

10.  Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology.

Authors:  Megan E Larson; Mathew A Sherman; Susan Greimel; Michael Kuskowski; Julie A Schneider; David A Bennett; Sylvain E Lesné
Journal:  J Neurosci       Date:  2012-07-25       Impact factor: 6.167

View more
  18 in total

1.  Effect of Some Growth Factors on Tissue Transglutaminase Overexpression Induced by β-Amyloid in Olfactory Ensheathing Cells.

Authors:  Rosalia Pellitteri; Roberta Bonfanti; Michela Spatuzza; Maria Teresa Cambria; Mariacristina Ferrara; Giuseppina Raciti; Agata Campisi
Journal:  Mol Neurobiol       Date:  2016-10-18       Impact factor: 5.590

2.  Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program.

Authors:  Thomas G Beach; Charles H Adler; Lucia I Sue; Geidy Serrano; Holly A Shill; Douglas G Walker; LihFen Lue; Alex E Roher; Brittany N Dugger; Chera Maarouf; Alex C Birdsill; Anthony Intorcia; Megan Saxon-Labelle; Joel Pullen; Alexander Scroggins; Jessica Filon; Sarah Scott; Brittany Hoffman; Angelica Garcia; John N Caviness; Joseph G Hentz; Erika Driver-Dunckley; Sandra A Jacobson; Kathryn J Davis; Christine M Belden; Kathy E Long; Michael Malek-Ahmadi; Jessica J Powell; Lisa D Gale; Lisa R Nicholson; Richard J Caselli; Bryan K Woodruff; Steven Z Rapscak; Geoffrey L Ahern; Jiong Shi; Anna D Burke; Eric M Reiman; Marwan N Sabbagh
Journal:  Neuropathology       Date:  2015-01-26       Impact factor: 1.906

3.  Inflammatory Pathways Are Impaired in Alzheimer Disease and Differentially Associated With Apolipoprotein E Status.

Authors:  Courtney M Kloske; Adam J Dugan; Erica M Weekman; Zachary Winder; Ela Patel; Peter T Nelson; David W Fardo; Donna M Wilcock
Journal:  J Neuropathol Exp Neurol       Date:  2021-10-26       Impact factor: 3.148

4.  Structural Analysis of Human Fascin-1: Essential Protein for Actin Filaments Bundling.

Authors:  Jeong Min Chung; Osamu Sato; Reiko Ikebe; Sangmin Lee; Mitsuo Ikebe; Hyun Suk Jung
Journal:  Life (Basel)       Date:  2022-06-06

Review 5.  Actin regulation by tropomodulin and tropomyosin in neuronal morphogenesis and function.

Authors:  Kevin T Gray; Alla S Kostyukova; Thomas Fath
Journal:  Mol Cell Neurosci       Date:  2017-04-19       Impact factor: 4.314

6.  Subjects harboring presenilin familial Alzheimer's disease mutations exhibit diverse white matter biochemistry alterations.

Authors:  Alex E Roher; Chera L Maarouf; Michael Malek-Ahmadi; Jeffrey Wilson; Tyler A Kokjohn; Ian D Daugs; Charisse M Whiteside; Walter M Kalback; Mimi P Macias; Sandra A Jacobson; Marwan N Sabbagh; Bernardino Ghetti; Thomas G Beach
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

7.  Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer's disease.

Authors:  Eleanor Drummond; Shruti Nayak; Arline Faustin; Geoffrey Pires; Richard A Hickman; Manor Askenazi; Mark Cohen; Tracy Haldiman; Chae Kim; Xiaoxia Han; Yongzhao Shao; Jiri G Safar; Beatrix Ueberheide; Thomas Wisniewski
Journal:  Acta Neuropathol       Date:  2017-03-04       Impact factor: 15.887

8.  Soluble amyloid beta levels are elevated in the white matter of Alzheimer's patients, independent of cortical plaque severity.

Authors:  Lyndsey E Collins-Praino; Yitshak I Francis; Erica Y Griffith; Anne F Wiegman; Jonathan Urbach; Arlene Lawton; Lawrence S Honig; Etty Cortes; Jean Paul G Vonsattel; Peter D Canoll; James E Goldman; Adam M Brickman
Journal:  Acta Neuropathol Commun       Date:  2014-08-17       Impact factor: 7.801

9.  Vascular Lesions, APOE ε4, and Tau Pathology in Alzheimer Disease.

Authors:  Jodie B Nichols; Michael Malek-Ahmadi; Pierre N Tariot; Geidy E Serrano; Lucia I Sue; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2021-02-22       Impact factor: 3.685

10.  A platelet protein biochip rapidly detects an Alzheimer's disease-specific phenotype.

Authors:  Michael Veitinger; Rudolf Oehler; Ellen Umlauf; Roland Baumgartner; Georg Schmidt; Christopher Gerner; Rita Babeluk; Johannes Attems; Goran Mitulovic; Eduard Rappold; John Lamont; Maria Zellner
Journal:  Acta Neuropathol       Date:  2014-09-24       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.